Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experienceMariangela Ciccarese, Giammarco Surico, Antonio Febbraro et al.|Breast Cancer Research and Treatment|2017Cited by 12
BRCA1 and 2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter AnalysisPalma Fedele, Gennaro Gadaleta‐Caldarola, Alessandro Rizzo et al.|Journal of Clinical Medicine|2025Cited by 4
Impact of Chemotherapy Dose Intensity on Pathological Complete Response in Pembrolizumab-Treated Early Triple-Negative Breast Cancer: A Real-World Multicenter AnalysisPalma Fedele, Gennaro Gadaleta‐Caldarola, Luigia Stefania Stucci et al.|Cancers|2025Cited by 3
BRCA1/2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter AnalysisPalma Fedele, Gennaro Gadaleta‐Caldarola, Alessandro Rizzo et al.|Preprints.org|2025Cited by 1
Abstract P4-13-15: Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real world population of hormone receptor positive advanced breast cancer: A multicenter Italian experienceR. Forcignanò, Mariangela Ciccarese, Antonio Cusmai et al.|Cancer Research|2016Cited by 0